SEC Comment Letter 0000000000-24-004510 to Aspira Women's Health Inc. (AWHL)
Aspira Women's Health Inc.
Date: April 23, 2024 · CIK: 0000926617 · Accession: 0000000000-24-004510
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-278867
Letter
United States securities and exchange commission logo April 23, 2024 Nicole Sandford Chief Executive Officer & Director Aspira Women's Health Inc. 12117 Bee Caves Road, Building III, Suite 100 Austin, Texas 78738 Re:Aspira Women's Health Inc. Registration Statement on Form S-3 Filed April 22, 2024 File No. 333-278867 Dear Nicole Sandford: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tamika Sheppard at 202-551-8346 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Josh Seidenfeld
Show Raw Text
United States securities and exchange commission logo
April 23, 2024
Nicole Sandford
Chief Executive Officer & Director
Aspira Women's Health Inc.
12117 Bee Caves Road, Building III, Suite 100
Austin, Texas 78738
Re:Aspira Women's Health Inc.
Registration Statement on Form S-3
Filed April 22, 2024
File No. 333-278867
Dear Nicole Sandford:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tamika Sheppard at 202-551-8346 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Josh Seidenfeld